Authors
Latest:
Loss of Exclusivity: Strategies to Maximize Product ValueLoss of exclusivity (LOE) doesn’t have to be the death knell for branded drug revenue streams. The key approaches to preserving meaningful value well into the post-patent-loss future are outlined.
Latest:
Loss of Exclusivity: Strategies to Maximize Product ValueLoss of exclusivity (LOE) doesn’t have to be the death knell for branded drug revenue streams. The key approaches to preserving meaningful value well into the post-patent-loss future are outlined.
Latest:
Loss of Exclusivity: Strategies to Maximize Product ValueLoss of exclusivity (LOE) doesn’t have to be the death knell for branded drug revenue streams. The key approaches to preserving meaningful value well into the post-patent-loss future are outlined.
Latest:
Human Rights on the Pharma Risk Management AgendaMilana Chamberlain and George Cameron ask: is it time for pharma to start using human rights language?
Latest:
PhRMA Dismayed by Global IPR ReportPharmaceutical Research and Manufacturers of America (PhRMA) International Vice-President Jay Taylor has expressed the organization’s concerns over the Office of the United States Trade Representative’s (USTR) 2013 Special 301 Report.
Latest:
Tufts Figures on Drug Development Spark DebateThe Tufts University Center for the Study of Drug Development (CSDD) released its latest research on the costs and timeframes required for launching a new drug.
Latest:
Indonesian Pharma Poised for Strong GrowthCPhI report notes that the Indonesian pharma market is on the brink of a regional manufacturing boom, with market capitalizations and company values rising.
Latest:
October 2016: Seizing the Commercial Opportunity from Big Data in Life SciencesLife sciences: the time is now for a comprehensive big data strategy.
Latest:
October 2016: Wisdom for the JourneyIn patient support programs, success-and your ROI-rests on making that vital connection between technology and the human touch.
Latest:
Biosimilars Gaining Traction as Regulator Confidence GrowsBiosimilars are gaining more support among payers and physicians, but more needs to be done to explain their benefits as well as their safety and efficacy profiles, writes Barbara Testa.
Latest:
Executive Pay and InnovationHow the need for biopharma innovation extends to questions around executive compensation.
Latest:
The State of Market Insights in PharmaIt's time to take advantage of a nascent technology embrace taking hold among market insights professionals.
Latest:
Going to the EdgeHow a Manufacturing Excellence program can deliver competitive advantage to a fast-changing global product mix-at lower cost, and with an unexpected workforce dividend to boot.
Latest:
Going to the EdgeHow a Manufacturing Excellence program can deliver competitive advantage to a fast-changing global product mix-at lower cost, and with an unexpected workforce dividend to boot.
Latest:
Going to the EdgeHow a Manufacturing Excellence program can deliver competitive advantage to a fast-changing global product mix-at lower cost, and with an unexpected workforce dividend to boot.
Latest:
The Winning Edge in Emerging MarketsHow a strong corporate board can help ignite success in these regions.
Latest:
Electrical Pulses Spark New Ways to Treat Diseases (SPONSORED)Anthony Arnold offers an overview and update of bioelectronic medicine.
Latest:
Polish Bid for Biotech GloryPoland's government is aiming to make the Eastern European country a biotech powerhouse.
Latest:
The Shrinking CMO IndustryExits from the CMO industry are a more recent development that seems to be picking up momentum.
Latest:
FDA, Industry Face Challenges in the Year AheadUnprecedented policy and access issues threaten R&D momentum.
Latest:
FDA Speeds New Guidances to Inform Clinical Research During PandemicThe need for new therapies to treat coronavirus patients has prompted an onslaught of advisories from FDA clarifying how sponsors should assess and implement changes necessary to fit this new reality.
Latest:
Industry Slams Medicare Price Negotiation SchemeRecent lawsuits are challenging the constitutionality of provisions in the Inflation Reduction Act.
Latest:
New Year, Next Steps in Digital TransformationFive predictions on evolution of data and predictive insights that could be critical for pharma go-to-market strategies.
Latest:
January 2017: Small-Company Attention, Big-Company ResourcesGayle Johnston explains what makes CuraScript SD uniquely able to serve its broad range of customers.
Latest:
Balancing Privacy and Access to Health Information in the Age of Big DataThe Expert Determination standard of protecting patient privacy can answer the growing demand for better data for research and analytics in healthcare.
